newsfilter
← Latest News
Business Wire·

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

  • Zura Bio Limited (NASDAQ: ZURA) senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY.
  • The Company will conduct one-on-one investor meetings on the same day as the summit.
  • A live webcast of the presentation will be available in the Investors section of the Company's website, with a replay archived for at least 30 days.
  • Zura is a clinical-stage multi-asset immunology company developing novel dual-pathway antibodies for autoimmune & inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is being evaluated in two Phase 2 studies: TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis.
  • Product candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are being evaluated for various autoimmune & inflammatory conditions.